🔍

Fermenta Biotech Ltd (506414)

📊 BSE: 506414 🏢 Pharmaceuticals 📢 Latest filing: 30 Sep 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Fermenta Biotech's revenue was ₹122 Cr (-10.4% year on year, -0.1% on the previous quarter), and net profit ₹9.5 Cr (-56.7% year on year); the operating margin was 14.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹122	-10.4%	-0.1%
Operating profit	₹18.1	-35.5%	-9.7%
Net profit	₹9.5	-56.7%	-49.8%
EPS (₹)	3.31	-55.4%	-49.2%
Operating margin	14.8%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Promoter Preeti Thakkar Sells 3.96% Stake (11.66 Lakh Shares) in Fermenta Biotech

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 30 Sep 2026, 11:15 AM

Promoter Preeti Thakkar has sold 11,65,938 equity shares, representing 3.96% of the share capital of Fermenta Biotech Limited, via an open market transaction on September 28, 2026. Following the sale, her individual holding has decreased from 7.61% (22,40,376 shares) to 3.65% (10,74,438 shares). At current market prices, the sold stake represents approximately Rs 54.7 crore in value against the company's total market cap of Rs 1,351 crore. Total promoter group holding stood at 64.08% prior to this transaction.

Promoter Preeti Thakkar sold 11,65,938 shares (3.96% of total equity) via open market on September 28, 2026
Pre-transaction holding was 22,40,376 shares (7.61% of voting capital)
Post-transaction holding stands at 10,74,438 shares (3.65% of voting capital)
Total diluted share capital of the company remains at 2,94,30,987 shares (Rs 14,71,54,935)

💡 Track the upcoming quarterly shareholding pattern to see the overall change in aggregate promoter group holding and whether institutional buyers absorbed the block.

Fermenta Biotech Schedules One-to-One Investor Meeting on September 3, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 04:00 PM

Fermenta Biotech has intimated an upcoming physical, one-to-one investor meeting scheduled for September 3, 2026, in Mumbai. The company noted that discussions will be based on publicly available press releases and investor presentations on its website. No unpublished price sensitive information (UPSI) is intended to be discussed during the interaction.

Meeting scheduled for September 3, 2026
Meeting format: Physical, one-to-one interaction in Mumbai
Company confirmed discussions will rely solely on publicly available information with no UPSI shared

💡 Track subsequent post-meet presentation uploads or exchange disclosures, if any, for any strategic updates.

Fermenta Biotech Schedules 1-on-1 Investor Meeting on August 21, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 17 Aug 2026, 04:48 PM

Fermenta Biotech Ltd has informed the exchanges regarding an upcoming one-to-one investor meeting scheduled for August 21, 2026. The meeting will take place in a physical format in Mumbai. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared, and discussions will be based on publicly available investor presentations.

One-to-one investor meeting scheduled for August 21, 2026
Meeting mode is physical, taking place in Mumbai
Company confirmed discussions will use publicly available presentations and no UPSI will be shared

💡 Track subsequent post-meet disclosures or investor presentations uploaded to the stock exchanges for any updates on operational strategies.

CARE Upgrades Fermenta Biotech's Long-Term Rating to 'BBB+' on Rs 172.98 Cr Bank Facilities

🟢 POSITIVE ⭐ 9/10

OTHER 📅 17 Aug 2026, 04:40 PM

CARE Ratings Limited has upgraded Fermenta Biotech's credit ratings across its bank facilities totalling Rs 172.98 crore. The rating for long-term bank facilities was upgraded to 'CARE BBB+; Stable' from 'CARE BBB; Stable', with the rated limit enhanced to Rs 166.73 crore from Rs 118.94 crore. Short-term bank facilities of Rs 6.25 crore were upgraded to 'CARE A2' from 'CARE A3+'. The upgrade reflects an improved credit risk profile relative to the company's existing debt of Rs 113 crore and net worth of Rs 406 crore.

Long-term bank facilities upgraded to CARE BBB+; Stable from CARE BBB; Stable
Long-term bank facility limits enhanced to Rs 166.73 crore from Rs 118.94 crore
Short-term bank facilities of Rs 6.25 crore upgraded to CARE A2 from CARE A3+
Total rated bank facilities aggregate to Rs 172.98 crore

💡 Track whether the credit rating upgrade leads to lower borrowing costs in upcoming quarterly finance costs, and monitor debt utilization from the enhanced facilities.

Fermenta Biotech Approves ₹3.75 Dividend and ₹100 Cr Related Party Transaction at 74th AGM

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 11 Aug 2026, 11:12 PM

Fermenta Biotech concluded its 74th Annual General Meeting, where shareholders approved a final dividend of ₹3.75 per share (75% of face value) for FY26. A key resolution passed was the approval for material related party transactions with its subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crore. This transaction limit is significant, representing approximately 19% of the company's TTM revenue of ₹525 crore. Additionally, the company authorized a commission of up to 1% of net profits for non-executive directors.

Approved a final dividend of ₹3.75 per equity share for the financial year ended March 31, 2026.
Authorized material related party transactions with Fermenta USA LLC up to a limit of ₹100 crore.
Approved commission for Non-Executive Directors up to an aggregate of 1% of net profits.
Confirmed dividend payment will be completed on or before August 21, 2026.
Re-appointed Ms. Rajeshwari Datla as a Non-Executive Director following her retirement by rotation.

💡 Investors should monitor the quarterly revenue contribution from the US subsidiary to see if the ₹100 crore transaction limit translates into actual sales growth.

₹110 Cr Capex Approved for Vitamin D3 Expansion; FY26 Revenue Hits Record ₹548 Cr

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 11 Aug 2026, 02:37 PM

Fermenta Biotech reported a record FY26 revenue of ₹548 Cr, up 14% YoY, with core EBITDA (excluding real estate) rising 44% to ₹120 Cr. The Board has approved a significant ₹110 Cr capex for expanding plant-source Vitamin D3 and biocatalysis enzymes at the Dahej facility, representing ~21% of TTM revenue. While PAT fell to ₹70 Cr from ₹76 Cr, the prior year was inflated by a ₹45 Cr one-off real estate gain, indicating improved core profitability. Free cash flow tripled to ₹62 Cr, providing a strong cushion for the planned expansion.

Approved ₹110 Cr capex for plant-source Vitamin D3, Calcifediol, and biocatalysis enzymes at Dahej
Core EBITDA (excluding real estate) grew 44% to ₹120 Cr in FY26
Free cash flow tripled to ₹62 Cr, funding the stepped-up capex requirements
Secured EDQM CEP for Vitamin D3 100 SD, opening European pharmaceutical markets
Granted Indian process patent for VITADEE Green® (plant-source Vitamin D3)

💡 Monitor the execution timeline of the ₹110 Cr Dahej expansion and the commercial ramp-up of plant-source Vitamin D3 in the European market following the CEP approval.

Fermenta Biotech Q1FY27: PAT Drops 56% YoY to ‹9.5 Cr; Human Nutrition Recovers 24% QoQ

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 01:47 PM

Fermenta Biotech reported a weak Q1FY27 on a YoY basis, with PAT declining 56% to ‹9.5 Cr, largely due to a high base in Q1FY26 which included ‹4.3 Cr of non-recurring income. Revenue fell 13% YoY to ‹126.2 Cr, though the core Human Nutrition segment showed resilience with a 24% sequential (QoQ) revenue growth. Animal Nutrition remains a major headwind, with volumes down 52% QoQ and realizations dropping 40% YoY. The company is pivoting towards India, which now accounts for 47% of revenue compared to 35% a year ago.

PAT fell 56% YoY to ‹9.5 Cr, impacted by the absence of non-recurring insurance and real estate income present in Q1FY26.
Human Nutrition revenue grew 24% QoQ to ‹76.5 Cr, driven by an 18% increase in segment volumes.
Animal Nutrition realizations crashed 40% YoY, leading to a 41% YoY revenue decline in that segment to ‹12.6 Cr.
Employee costs rose to 19% of revenue versus 16% in FY26, reflecting hiring for the upcoming Dahej facility scale-up.
India market contribution increased to 47% of consolidated revenue, up from 35% in the same quarter last year.

💡 Monitor the commercialization timeline of Calcifediol and the market uptake of VITADEE Green following its July 2026 FSSAI approval. Investors should watch if the sequential recovery in Human Nutrition can offset the continued pricing pressure in the Animal Nutrition segment.

Fermenta Biotech Q1FY27 PAT drops 56% YoY to ₹9.5 Cr; Human Nutrition volumes up 18% QoQ

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 11 Aug 2026, 01:37 PM

Fermenta Biotech reported a weak Q1FY27 with consolidated revenue at ₹126.2 cr, down 13% YoY, and PAT falling 56% to ₹9.5 cr. The decline was primarily driven by a 40% drop in Vitamin D3 Animal Nutrition realizations and a high base effect from non-recurring insurance and real estate income in Q1FY26. However, Human Nutrition volumes grew 18% QoQ, and the India market share increased to 47% of revenue. A key positive is the FSSAI approval for VITADEE Green® received in July 2026, targeting the domestic vegetarian market.

Consolidated PAT fell 56% YoY to ₹9.5 crore, impacted by a 40% drop in Animal Nutrition realizations.
Human Nutrition volumes increased 18% QoQ, contributing ₹76.5 crore to revenue (61% of total).
India's share of consolidated revenue rose to 47% in Q1FY27 from 35% in the previous year.
FSSAI approval for VITADEE Green® was received on July 6, 2026, for use in health supplements and food fortification.
Animal Nutrition revenue declined 41% YoY to ₹12.6 crore due to weak pricing and volume discipline.

💡 Monitor the commercialization timeline of the Dahej plant-based Vitamin D3 capacity and the market uptake of VITADEE Green® following FSSAI approval. Watch for stabilization in Animal Nutrition realizations, which significantly dragged down margins this quarter.

Fermenta Biotech Approves Q1 FY27 Results; TTM Revenue Stands at ₹525 Cr

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 01:26 PM

Fermenta Biotech has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The statutory auditors, M/s. SRBC & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting discrepancies. These results follow a fiscal year (FY26) where the company reported a revenue of ₹525 Cr and a PAT of ₹71 Cr. Investors should monitor if the company can improve its operating margins, which stood at 19% in FY26 compared to 25% in FY25.

Board meeting conducted on August 11, 2026, between 11:00 a.m. and 01:10 p.m.
Unaudited financial results approved for the quarter ended June 30, 2026
Statutory auditors M/s. SRBC & Co. LLP issued an unmodified opinion on the results
Company maintains a promoter holding of 64.08% as of the latest reporting period
TTM revenue of ₹525 Cr and TTM PAT of ₹71 Cr provide the baseline for current performance

💡 Investors should compare the Q1 FY27 revenue and operating margins against the Q1 FY26 revenue of ₹136 Cr and PAT of ₹22 Cr to determine if the growth trajectory is sustaining.

Fermenta Biotech Approves Q1 FY27 Results; Auditors Issue Unmodified Opinion

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 01:18 PM

Fermenta Biotech's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a meeting held on August 11, 2026. The statutory auditors, SRBC & Co. LLP, issued a limited review report with an unmodified opinion, indicating no significant accounting concerns. While the specific quarterly figures were not detailed in the cover letter, the company enters this period with a TTM revenue of ₹525 Cr and a TTM PAT of ₹71 Cr. Investors should compare the full results against the ₹136 Cr revenue and ₹22 Cr net profit recorded in the same quarter of the previous year (June 2025).

Board meeting conducted on August 11, 2026, between 11:00 a.m. and 01:10 p.m.
Statutory auditors M/s. SRBC & Co. LLP issued an unmodified opinion on the financial results.
Results approved for the first quarter of FY27, ending June 30, 2026.
Company maintains a TTM Operating Profit Margin of 19.0% as per latest available context.

💡 Review the detailed P&L statement to check if the operating profit margin has stabilized or improved from the 19% reported in FY26, compared to 25% in FY25.

Fermenta Biotech Schedules One-to-One Investor Meeting for August 17, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Aug 2026, 08:12 PM

Fermenta Biotech Ltd has announced a physical one-to-one investor meeting scheduled for August 17, 2026, in Mumbai. The company clarified that no unpublished price sensitive information (UPSI) will be discussed, with interactions limited to publicly available information. This meeting occurs against a backdrop of strong stock performance, with a 95.6% price return over the last three months. The company reported TTM revenue of ₹525 Cr and a PAT of ₹71 Cr for FY26.

One-to-one physical investor meeting scheduled for August 17, 2026, in Mumbai.
Company reported TTM revenue of ₹525 Cr and OPM of 19.0% for FY26.
Stock has delivered a 95.6% return over the last 3 months and 80.3% over 6 months.
Market capitalization stands at ₹1,629 Cr with a P/E ratio of 22.9.

💡 Investors should monitor the company's website for any updated investor presentations or meeting transcripts that may provide qualitative insights into the business outlook.

Fermenta Biotech Board Meeting on August 11, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 04 Aug 2026, 05:52 PM

Fermenta Biotech has scheduled a board meeting for August 11, 2026, to review and approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This is a routine regulatory requirement under SEBI regulations. The company reported a TTM revenue of ₹525 Cr and a PAT of ₹71 Cr as of the previous fiscal year. The trading window for insiders has been closed since July 1, 2026, and will remain so until 48 hours after the results are announced.

Board meeting scheduled for August 11, 2026, to approve Q1 results.
Trading window for insiders closed effective July 1, 2026.
Results cover the three-month period ended June 30, 2026.
Trading window to reopen 48 hours after the results declaration on August 11, 2026.

💡 Monitor the official results release on August 11 to assess if the company can improve its operating profit margin, which stood at 19% in FY26.

Fermenta Biotech Lists 2.94 Cr Equity Shares on NSE to Enhance Liquidity

🟢 POSITIVE ⭐ 4/10

ROUTINE 📅 04 Aug 2026, 05:33 PM

Fermenta Biotech Limited has successfully listed its 2,94,30,987 equity shares on the National Stock Exchange (NSE) effective August 4, 2026, under the symbol FERMENTA. The company, which has been listed on the BSE since 1977, is now dual-listed to improve accessibility, visibility, and price discovery. With a market capitalization of Rs 1,453 Cr and TTM revenue of Rs 525 Cr, this move aims to attract a wider community of investors. The listing coincides with the company's 75th anniversary of operations.

2,94,30,987 equity shares of face value ₹5 each admitted to dealings on the NSE
Company has maintained a public listing on the BSE for 49 years (since 1977)
Operates manufacturing facilities in 3 locations: Himachal Pradesh, Gujarat, and Andhra Pradesh
Serves a global customer base of over 400 clients across 60+ countries

💡 Monitor the shift in trading volumes from BSE to NSE over the coming weeks to assess improvements in liquidity and price discovery.

Fermenta Biotech to list 2.94 crore equity shares on NSE effective August 04, 2026

🟢 POSITIVE ⭐ 5/10

REGULATORY 📅 31 Jul 2026, 07:44 PM

Fermenta Biotech Limited has received approval to list its 2,94,30,987 equity shares on the National Stock Exchange (NSE) starting August 04, 2026. The company, which is currently listed on the BSE, will trade under the symbol 'FERMENTA'. This move is expected to enhance the stock's liquidity and visibility among institutional and retail investors. The company currently has a market capitalization of ₹1,355 crore and TTM revenue of ₹525 crore.

2,94,30,987 equity shares of ₹5 face value to be listed on NSE
Listing and admission to dealings effective from August 04, 2026
Company assigned the NSE trading symbol: FERMENTA
Follows the initial intimation regarding NSE listing dated June 16, 2026

💡 Investors should monitor the transition of trading volumes from BSE to NSE starting August 4. While business fundamentals remain unchanged, the dual listing typically improves price discovery and accessibility for institutional funds.

Fermenta Biotech to Hold One-to-One Investor Meeting on July 29, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Jul 2026, 02:35 PM

Fermenta Biotech Ltd has scheduled a one-to-one physical investor meeting in Mumbai on July 29, 2026. The company clarified that no unpublished price sensitive information (UPSI) will be discussed, and the interaction will focus on existing public disclosures. With a market capitalization of Rs 1,225 Cr and TTM revenue of Rs 525 Cr, this is a routine engagement to maintain investor relations.